Sinovac Files to Start Clinical Trial of Infant Pneumococcal Vaccine

Sinovac Biotech has filed an application with the SFDA to begin clinical trials of its 13-valent pneumococcal conjugate vaccine (PCV). The target market for the vaccine is infants under the age of two, a population that currently numbers 34 million in China. Sinovac also anticipates participating in a United Nations program that supplies PCV to developing nations. More details.... Stock Symbol: (NSDQ: SVA)